• Publications
  • Influence
Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery
TLDR
VHH-IR led to a much faster tumour accumulation with high tumour to background ratios as compared to trastuzumab-IR allowing same-day imaging for clinical investigation as well as image-guided surgery. Expand
VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.
TLDR
The role of VEGF-PET as a biomarker of dynamic angiogenic changes in tumors following treatment with the kinase inhibitor sunitinib is evaluated and its strengths are highlighted to allow serial analysis of angiogenesis changes in different areas within a tumor. Expand
Human Epidermal Growth Factor Receptor 3–Specific Tumor Uptake and Biodistribution of 89Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging
TLDR
Ex vivo biodistribution showed protein dose– and time-dependent distribution of 89Zr-MSB0010853 in all organs, and tumor uptake correlates with HER3 expression, which is in contrast to tumor uptake except for kidney uptake. Expand
Towards clinical VEGF imaging using the anti-VEGF antibody bevacizumab and Fab-fragment ranibizumab
TLDR
Non-invasive assessment of VEGF-levels in the micro-environment of the tumor could guide in the development and follow up of anti-VEGF targeted therapy. Expand
Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non‐Ig scaffolds
TLDR
An overview of specific protein properties and modifications that can affect biodistribution and tumor uptake of anticancer antibodies, antibody fragments, and nonimmunoglobulin scaffolds is provided. Expand
Biodistribution and PET Imaging of Labeled Bispecific T Cell–Engaging Antibody Targeting EpCAM
TLDR
The authors' data support using 89Zr and IRDye 800CW to evaluate tumor and tissue uptake kinetics of bispecific T cell engager antibody constructs in preclinical and clinical settings provides real-time information about AMG 110 distribution and tumor uptake in vivo. Expand
Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors
TLDR
89Zr-AMG211 showed dose-dependent CEA-specific tumor targeting and localization in viable tumor tissue and was manufactured according to Good Manufacturing Practice (GMP) guidelines for clinical trial NCT02760199. Expand
Abstract A85: Preclinical evaluation of the radiolabeled bispecific T-cell engager 89Zr-AMG 211 targeting CEA-positive tumors
TLDR
This study showed dose-dependent CEA-specific targeting of 89Zr-AMG 211 in LS174T bearing mice with the highest uptake 3 h after injection and a prolonged imageable tumor retention up to 48 h, and showed similar CEA binding as unlabeled AMG 211. Expand
...
1
2
...